Get Premium to unlock powerful stock data
Xeris Biopharma Holdings Inc logo

Xeris Biopharma Holdings Inc

$ 2.17 0 (0%) 08:08 PM EST
P/E:
At Loss
P/B:
3.05
Market Cap:
$ 294.10M
Enterprise V:
$ 299.93M
Volume:
716.14K
Avg Vol (2M):
1.81M
Also Trade In:
Volume:
716.14K
Market Cap $:
294.10M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.81M
Enterprise Value $:
299.93M
PB Ratio:
3.05
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Xeris Biopharma Holdings Inc
NAICS : 325412 SIC : 2834
180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601
Description
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Name Current Vs Industry Vs History
Cash-To-Debt 0.96
Equity-to-Asset 0.29
Debt-to-Equity 1.43
Debt-to-EBITDA -1.1
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2
Distress
Grey
Safe
Beneish M-Score 143.67
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 55.09
9-Day RSI 51.5
14-Day RSI 48.97
6-1 Month Momentum % 12.02
12-1 Month Momentum % -32.85

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.67
Quick Ratio 2.42
Cash Ratio 1.99
Days Inventory 304.19
Days Sales Outstanding 86.7
Days Payable 140.77

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -81.7

Financials (Next Earnings Date:2022-08-05 Est.)

XERS's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:XERS

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 63.683
EPS (TTM) ($) -1.47
Beta 2.25
Volatility % 77.11
14-Day RSI 48.97
14-Day ATR ($) 0.209563
20-Day SMA ($) 2.152
12-1 Month Momentum % -32.85
52-Week Range ($) 1.25 - 4.98
Shares Outstanding (Mil) 135.53

Piotroski F-Score Details

Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Xeris Biopharma Holdings Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More